The changing and dynamic epidemiology of meningococcal disease (Q37969481)

26 August 2017

The changing and dynamic epidemiology of meningococcal disease (English)

1 reference

26 August 2017

1 reference

Shamez N Ladhani

6

0 references

Julie Bettinger

object named as

Julie A Bettinger

2

0 references

Brian Greenwood

3

object named as

Brian Greenwood

1 reference

26 August 2017

1

Scott A Halperin

1 reference

26 August 2017

4

Lee H Harrison

1 reference

26 August 2017

Jane Jelfs

5

1 reference

26 August 2017

Peter McIntyre

7

1 reference

26 August 2017

Mary E Ramsay

8

1 reference

26 August 2017

Marco A P Sáfadi

9

1 reference

26 August 2017

language of work or name

English

0 references

publication date

15 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

30 Suppl 2

1 reference

26 August 2017

B26-36

1 reference

Global epidemiology of meningococcal disease.

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

7 January 2021

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region--current status and needs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Increase in Neisseria meningitidis serogroup W135, Niger, 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Acute childhood bacterial meningitis in Luanda, Angola

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Surveillance of acute bacterial meningitis among children admitted to a district hospital in rural Mozambique.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Bacterial meningitis and Haemophilus influenzae type b conjugate vaccine, Malawi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Acute bacterial meningitis at the 'Complexe Pédiatrique' of Bangui, Central African Republic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Epidemiology, molecular characterization and antibiotic resistance of Neisseria meningitidis from patients ≤15 years in Manhiça, rural Mozambique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Meningococcal disease in Asia: an under-recognized public health burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

The epidemiology of meningococcal disease in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Letter: Recognition of diphtheria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Outbreak of meningococcal disease in and around New Delhi, India, 2005-2006: a report from a tertiary care hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Emergence and disappearance of W135 meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Modern trends in mortality from meningococcal disease in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Review of meningococcal group B vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Epidemiology and meningococcal serogroup distribution in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Naturally occurring lipid A mutants in neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Carriage of meningococci by university students, United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Meningococcal glycoconjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

B:2a:p1.5 meningococcal strains likely arisen from capsular switching event still spreading in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Meningococcal disease and vaccination in North America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

IMPACT after 17 years: Lessons learned about successful networking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

International Circumpolar Surveillance, an Arctic network for the surveillance of infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

inferred from DOI database lookup

7 January 2021

based on heuristic

Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Phenotypic characterization of Neisseria meningitidis strains isolated from invasive disease in Brazil from 1990 to 2001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in São Paulo, Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Serogroup Y meningococcal disease, Colombia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Surveillance for invasive meningococcal disease in children, US-Mexico border, 2005-2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

The epidemiological impact of antimeningococcal B vaccination in Cuba

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

Epidemic meningococcal meningitis in central Australia, 1987-1991.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

inferred from DOI database lookup

7 January 2021

based on heuristic

[Meningococcal disease in São Paulo, Brazil, in the 20th century: epidemiological characteristics]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.032

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.12.032

1 reference

26 August 2017

1 reference